These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18215206)

  • 1. Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis.
    Marroni F; Cipollini G; Peissel B; D'Andrea E; Pensabene M; Radice P; Caligo MA; Presciuttini S; Bevilacqua G
    Ann Hum Genet; 2008 May; 72(Pt 3):310-8. PubMed ID: 18215206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
    Bergman A; Einbeigi Z; Olofsson U; Taib Z; Wallgren A; Karlsson P; Wahlström J; Martinsson T; Nordling M
    Eur J Hum Genet; 2001 Oct; 9(10):787-93. PubMed ID: 11781691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?
    Russo A; Calò V; Bruno L; Schirò V; Agnese V; Cascio S; Foddai E; Fanale D; Rizzo S; Di Gaudio F; Gulotta E; Surmacz E; Di Fede G; Bazan V
    Breast Cancer Res Treat; 2009 Jan; 113(1):67-70. PubMed ID: 18228134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (GCG)11 founder mutation in the PABPN1 gene of OPMD Uruguayan families.
    Rodríguez M; Camejo C; Bertoni B; Braida C; Rodríguez MM; Brais B; Medici M; Roche L
    Neuromuscul Disord; 2005 Feb; 15(2):185-90. PubMed ID: 15694141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of a founder effect for the protein C gene 3363 inserted C mutation in thrombophilic pedigrees of French origin.
    Couture P; Bovill EG; Demers C; Simard J; Delage R; Scott BT; Valliere JE; Callas PW; Jomphe M; Rosendaal FR; Aiach M; Long GL
    Thromb Haemost; 2001 Oct; 86(4):1000-6. PubMed ID: 11686315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa.
    Richard P; Gaudon K; Haddad H; Ammar AB; Genin E; Bauché S; Paturneau-Jouas M; Müller JS; Lochmüller H; Grid D; Hamri A; Nouioua S; Tazir M; Mayer M; Desnuelle C; Barois A; Chabrol B; Pouget J; Koenig J; Gouider-Khouja N; Hentati F; Eymard B; Hantaï D
    Neurology; 2008 Dec; 71(24):1967-72. PubMed ID: 19064877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.
    Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
    Genes Chromosomes Cancer; 2001 Jun; 31(2):107-16. PubMed ID: 11319798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population history and infrequent mutations: how old is a rare mutation? GUCY2D as a worked example.
    Hanein S; Perrault I; Gerber S; Delphin N; Benezra D; Shalev S; Carmi R; Feingold J; Dufier JL; Munnich A; Kaplan J; Rozet JM; Jeanpierre M
    Eur J Hum Genet; 2008 Jan; 16(1):115-23. PubMed ID: 17684531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Founder effect in spinal and bulbar muscular atrophy (SBMA) in Scandinavia.
    Lund A; Udd B; Juvonen V; Andersen PM; Cederquist K; Ronnevi LO; Sistonen P; Sörensen SA; Tranebjaerg L; Wallgren-Pettersson C; Savontaus ML
    Eur J Hum Genet; 2000 Aug; 8(8):631-6. PubMed ID: 10951525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.
    Lesca G; Genin E; Blachier C; Olivieri C; Coulet F; Brunet G; Dupuis-Girod S; Buscarini E; Soubrier F; Calender A; Danesino C; Giraud S; Plauchu H;
    Eur J Hum Genet; 2008 Jun; 16(6):742-9. PubMed ID: 18285823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using linked markers to infer the age of a mutation.
    Rannala B; Bertorelle G
    Hum Mutat; 2001 Aug; 18(2):87-100. PubMed ID: 11462233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
    Vézina H; Durocher F; Dumont M; Houde L; Szabo C; Tranchant M; Chiquette J; Plante M; Laframboise R; Lépine J; Nevanlinna H; Stoppa-Lyonnet D; Goldgar D; Bridge P; Simard J
    Hum Genet; 2005 Jul; 117(2-3):119-32. PubMed ID: 15883839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a founder BRCA1 mutation in the Moroccan population.
    Quiles F; Teulé À; Martinussen Tandstad N; Feliubadaló L; Tornero E; Del Valle J; Menéndez M; Salinas M; Wethe Rognlien V; Velasco A; Izquierdo A; Capellá G; Brunet J; Lázaro C
    Clin Genet; 2016 Oct; 90(4):361-5. PubMed ID: 26864382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Founder effect with variable age at onset in Arab families with Lafora disease and EPM2A mutation.
    Gomez-Abad C; Afawi Z; Korczyn AD; Misk A; Shalev SA; Spiegel R; Lerman-Sagie T; Lev D; Kron KL; Gómez-Garre P; Serratosa JM; Berkovic SF
    Epilepsia; 2007 May; 48(5):1011-4. PubMed ID: 17509003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relating two deep-rooted pedigrees from Central Germany by high-resolution Y-STR haplotyping.
    Kayser M; Vermeulen M; Knoblauch H; Schuster H; Krawczak M; Roewer L
    Forensic Sci Int Genet; 2007 Jun; 1(2):125-8. PubMed ID: 19083742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome.
    da Costa EC; Vargas FR; Moreira AS; Lourenço JJ; Caleffi M; Ashton-Prolla P; Martins Moreira MA
    Cancer Genet Cytogenet; 2008 Jul; 184(1):62-6. PubMed ID: 18558292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C329X in KRIT1 is a founder mutation among CCM patients in Sardinia.
    Cau M; Loi M; Melis M; Congiu R; Loi A; Meloni C; Serrenti M; Addis M; Melis MA
    Eur J Med Genet; 2009; 52(5):344-8. PubMed ID: 19454328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Origins and prevalence of the American Founder Mutation of MSH2.
    Clendenning M; Baze ME; Sun S; Walsh K; Liyanarachchi S; Fix D; Schunemann V; Comeras I; Deacon M; Lynch JF; Gong G; Thomas BC; Thibodeau SN; Lynch HT; Hampel H; de la Chapelle A
    Cancer Res; 2008 Apr; 68(7):2145-53. PubMed ID: 18381419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial Mediterranean Fever in Lebanon: founder effects for different MEFV mutations.
    Jalkh N; Génin E; Chouery E; Delague V; Medlej-Hashim M; Idrac CA; Mégarbané A; Serre JL
    Ann Hum Genet; 2008 Jan; 72(Pt 1):41-7. PubMed ID: 17711558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.